✉news BusinessRetail first seen 13 h ago, last 4 min ago, peak #5
Retail Traders Speculate SLS, IBRX Could Join Nasdaq-100 After Moderna
Original: SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
Retail investors are speculating that small-cap biotechs Sellas Life Sciences (SLS) and Immatics-adjacent name IBRX could be next in line for Nasdaq-100 inclusion, after Moderna (MRNA) landed a spot in the index. Traders argue index eligibility could drive sharp rallies in the smaller stocks, with one saying 'it will be SLS next'. Nasdaq-100 additions typically trigger buying from index funds tracking the benchmark.
Why now: Modernas addition to the Nasdaq-100 has traders betting on which small-cap biotech could be added next, hoping for index-driven rallies.
SLS (Sellas Life Sciences)IBRXModernaNasdaq-100
Rank over time, top of the chart is #1. 11 snapshots from 13 h ago to 4 min ago.
Evidence
- SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’ · Stocktwits
API: https://socialmediatrends-api.osmike.com/v1/trends/928514